CORT — CORCEPT THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1088856 ·
Last close
$70.07
Market Cap
$7.67B
52W High
$126.38
52W Low
$28.66
ADV30
1,107,478
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 340,472,000 | 335,864,000 | 114,724,000 | 126,778,000 | 1,034,027,000 | 98,720,000 | 200,287,000 |
| Jun 2026 | 256,147,000 | 252,086,000 | 41,300,000 | 42,987,000 | 888,702,000 | 111,039,000 | 182,926,000 |
| Mar 2026 | 164,903,000 | 162,020,000 | -49,601,000 | -31,761,000 | 814,881,000 | 108,738,000 | 176,894,000 |
| Dec 2025 | 202,125,000 | 199,580,000 | 4,487,000 | 24,288,000 | 836,651,000 | 120,495,000 | 188,846,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$198,110,000
Investing CF
$-168,529,000
Financing CF
$-56,378,000
CapEx
$-3,488,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.27
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$781,391,000
Inventory
$11,907,000
Receivables
$111,061,000
ST Investments
$271,983,000
EBIT TTM
$110,910,000
Pretax Income TTM
$131,433,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$963,646,976
EBITDA
$113,138,000
Free Cash Flow
$132,181,752
Enterprise Value
$7,602,463,232
Total Cash
$370,703,008
Total Debt
$8,991,000
Shares Out
109,443,109
Trailing EPS
$1.33
Book Value
$7.62
ROE
22.1%
ROA
7.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 761,407,000 | 44,797,000 | 99,652,000 | 836,651,000 | 188,846,000 | 647,805,000 | 141,996,000 |
| Dec 2024 | 675,040,000 | 136,951,000 | 141,209,000 | 840,553,000 | 160,964,000 | 679,589,000 | 198,295,000 |
| Dec 2023 | 482,375,000 | 107,282,000 | 106,140,000 | 621,517,000 | 114,812,000 | 506,705,000 | 126,681,000 |
| Dec 2022 | 401,858,000 | 112,634,000 | 101,418,000 | 583,430,000 | 81,588,000 | 501,842,000 | 120,323,000 |
TTM Snapshot
Revenues TTM
$830,813,000
NetIncome TTM
$55,182,000
OpCashFlow TTM
—
Assets (Latest)
$888,702,000
Forward EPS
$4.22
Max Pain — expiry 2026-12-18
max pain strike: $85.00 · spot: $67.79 · call oi: 4,183 · put oi: 6,997
Expected Move to 2026-12-18:
±$14.80
(21.83%) —
implied range
$52.99 –
$82.59
· ATM straddle on $70.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ALKS | Alkermes plc. | $7.64B | $45.45 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $7.36B | $21.12 | — |
| PTGX | Protagonist Therapeutics, Inc | $8.07B | $124.67 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $8.08B | $116.61 | — |
| CYTK | CYTOKINETICS INC | $7.20B | $51.65 | — |
News headlines (Yahoo Finance, 1h cache)
What Is Driving The Move In Corcept Therapeutics Stock?
2026-11-18 11:29 · Yahoo
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
2026-11-16 13:00 · Yahoo
Can You Justify Buying Corcept Stock Today?
2026-11-06 12:20 · Yahoo
Corcept Therapeutics (CORT) Faces A Valuation Test As Profit Jumps And Pipeline Hopes Build
2026-11-06 06:13 · Yahoo
Corcept Therapeutics Incorporated Q3 2026 Earnings Call Summary
2026-11-05 01:42 · Yahoo
Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64% as ...
2026-11-04 19:05 · Yahoo
Corcept Therapeutics (CORT) Q3 2026 Earnings Call Transcript
2026-11-04 15:45 · Yahoo
Corcept Therapeutics Q3 Earnings Call Highlights
2026-11-04 00:14 · Yahoo
Corcept Therapeutics falls on guidance despite earnings beat
2026-11-03 22:20 · Yahoo
Corcept Therapeutics (CORT) Q3 Earnings and Revenues Surpass Estimates
2026-11-03 21:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.